These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3189171)

  • 1. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy.
    Sherrid M; Delia E; Dwyer E
    Am J Cardiol; 1988 Nov; 62(16):1085-8. PubMed ID: 3189171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
    Kajimoto K; Imai T; Minami Y; Kasanuki H
    Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy.
    Matsubara H; Nakatani S; Nagata S; Ishikura F; Katagiri Y; Ohe T; Miyatake K
    J Am Coll Cardiol; 1995 Sep; 26(3):768-75. PubMed ID: 7642872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disopyramide use in infants and children with hypertrophic cardiomyopathy.
    O'Connor MJ; Miller K; Shaddy RE; Lin KY; Hanna BD; Ravishankar C; Rossano JW
    Cardiol Young; 2018 Apr; 28(4):530-535. PubMed ID: 29513203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
    Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ
    J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers of responsiveness to disopyramide in patients with hypertrophic cardiomyopathy.
    Habib M; Hoss S; Bruchal-Garbicz B; Chan RH; Rakowski H; Williams L; Adler A
    Int J Cardiol; 2019 Dec; 297():75-82. PubMed ID: 31615649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration.
    Pollick C
    Am J Cardiol; 1988 Dec; 62(17):1252-5. PubMed ID: 3057852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Beneficial effects of disopyramide on left ventricular outflow obstruction in a case of hypertrophic obstructive cardiomyopathy].
    Terrosu P; Franceschino V; Contini GM; Dore L; Ibba GV
    G Ital Cardiol; 1984 Jan; 14(1):63-6. PubMed ID: 6538527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Doppler and echocardiographic assessments of effects of disopyramide on non-obstructive hypertrophic cardiomyopathy].
    Nagashima J
    J Cardiol; 1991; 21(1):75-86. PubMed ID: 1817183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration.
    Pollick C; Kimball B; Henderson M; Wigle ED
    Am J Cardiol; 1988 Dec; 62(17):1248-51. PubMed ID: 3195486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy.
    Kimball BP; Bui S; Wigle ED
    Am Heart J; 1993 Jun; 125(6):1691-7. PubMed ID: 8498312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral disopyramide for the acute treatment of severe outflow obstruction in hypertrophic cardiomyopathy in the ICU setting.
    Sirak TE; Sherrid MV
    Chest; 2008 May; 133(5):1243-6. PubMed ID: 18460523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disopyramide as a negative inotrope in obstructive cardiomyopathy in children.
    Duncan WJ; Tyrrell MJ; Bharadwaj BB
    Can J Cardiol; 1991 Mar; 7(2):81-6. PubMed ID: 2049687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
    Verlinden NJ; Coons JC
    Pharmacotherapy; 2015 Dec; 35(12):1164-72. PubMed ID: 26684556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide.
    Haruki S; Minami Y; Suzuki A; Hagiwara N
    Heart Vessels; 2015 Sep; 30(5):604-10. PubMed ID: 24917414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy.
    Minami Y; Kajimoto K; Kawana M; Hagiwara N; Sherrid MV
    Int J Cardiol; 2010 May; 141(2):195-7. PubMed ID: 19097655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of disopyramide and propranolol in hypertrophic cardiomyopathy.
    Cokkinos DV; Salpeas D; Ioannou NE; Christoulas S
    Can J Cardiol; 1989; 5(1):33-6. PubMed ID: 2920304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy.
    Hongo M; Nakatsuka T; Takenaka H; Tanaka M; Watanabe N; Yazaki Y; Sekiguchi M
    Cardiology; 1996; 87(1):6-11. PubMed ID: 8631046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of continuous intravenous drip infusion of disopyramide in hypertrophic obstructive cardiomyopathy during cardiogenic shock: a case report].
    Kajimoto K; Harada T; Imamura K; Matsuda N; Niki K; Hagiwara N; Kasanuki H
    J Cardiol; 2000 Mar; 35(3):197-203. PubMed ID: 10808427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disopyramide is a safe and effective treatment for children with obstructive hypertrophic cardiomyopathy.
    Topriceanu CC; Field E; Boleti O; Cervi E; Kaski JP; Norrish G
    Int J Cardiol; 2023 Jan; 371():523-525. PubMed ID: 36174821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.